38540171|t|Ferroptosis in Cardiovascular Disease and Cardiomyopathies: Therapeutic Implications of Glutathione and Iron Chelating Agents.
38540171|a|This review explores ferroptosis, a form of regulated cell death reliant on iron-induced phospholipid peroxidation, in diverse physiological and pathological contexts, including neurodegenerative disorders, and ischemia-reperfusion. In the realm of cardiovascular diseases, it significantly contributes to cardiomyopathies, including dilated cardiomyopathy, hypertrophic cardiomyopathy, and restrictive cardiomyopathy. Ferroptosis involves intricate interactions within cellular iron metabolism, lipid peroxidation, and the balance between polyunsaturated and monounsaturated fatty acids. Molecularly, factors like p53 and NRF2 impact cellular susceptibility to ferroptosis under oxidative stress. Understanding ferroptosis is vital in cardiomyopathies, where cardiac myocytes heavily depend on aerobic respiration, with iron playing a pivotal role. Dysregulation of the antioxidant enzyme GPX4 is linked to cardiomyopathies, emphasizing its significance. Ferroptosis's role in myocardial ischemia-reperfusion injury, exacerbated in diabetes, underscores its relevance in cardiovascular conditions. This review explores the connection between ferroptosis, the NRF2 pathway, and atherosclerosis, emphasizing their roles in protecting cells from oxidative stress and maintaining iron balance. It discusses the use of iron chelating agents in managing iron overload conditions, with associated benefits and challenges. Finally, it highlights the importance of exploring therapeutic strategies that enhance the glutathione (GSH) system and the potential of natural compounds like quercetin, terpenoids, and phenolic acids in reducing oxidative stress.
38540171	0	11	Ferroptosis	Disease	
38540171	15	37	Cardiovascular Disease	Disease	MESH:D002318
38540171	42	58	Cardiomyopathies	Disease	MESH:D009202
38540171	88	99	Glutathione	Chemical	MESH:D005978
38540171	104	108	Iron	Chemical	MESH:D007501
38540171	148	159	ferroptosis	Disease	
38540171	203	207	iron	Chemical	MESH:D007501
38540171	216	228	phospholipid	Chemical	MESH:D010743
38540171	305	332	neurodegenerative disorders	Disease	MESH:D019636
38540171	338	347	ischemia-	Disease	MESH:D007511
38540171	376	399	cardiovascular diseases	Disease	MESH:D002318
38540171	433	449	cardiomyopathies	Disease	MESH:D009202
38540171	461	483	dilated cardiomyopathy	Disease	MESH:D002311
38540171	485	512	hypertrophic cardiomyopathy	Disease	MESH:D002312
38540171	518	544	restrictive cardiomyopathy	Disease	MESH:D002313
38540171	546	557	Ferroptosis	Disease	
38540171	606	610	iron	Chemical	MESH:D007501
38540171	623	628	lipid	Chemical	MESH:D008055
38540171	667	714	polyunsaturated and monounsaturated fatty acids	Chemical	-
38540171	742	745	p53	Gene	7157
38540171	750	754	NRF2	Gene	4780
38540171	789	800	ferroptosis	Disease	
38540171	839	850	ferroptosis	Disease	
38540171	863	879	cardiomyopathies	Disease	MESH:D009202
38540171	948	952	iron	Chemical	MESH:D007501
38540171	1017	1021	GPX4	Gene	2879
38540171	1035	1051	cardiomyopathies	Disease	MESH:D009202
38540171	1105	1143	myocardial ischemia-reperfusion injury	Disease	MESH:D015427
38540171	1160	1168	diabetes	Disease	MESH:D003920
38540171	1199	1224	cardiovascular conditions	Disease	MESH:D002318
38540171	1270	1281	ferroptosis	Disease	
38540171	1287	1291	NRF2	Gene	4780
38540171	1305	1320	atherosclerosis	Disease	MESH:D050197
38540171	1404	1408	iron	Chemical	MESH:D007501
38540171	1442	1446	iron	Chemical	MESH:D007501
38540171	1476	1489	iron overload	Disease	MESH:D019190
38540171	1634	1645	glutathione	Chemical	MESH:D005978
38540171	1647	1650	GSH	Chemical	MESH:D005978
38540171	1703	1712	quercetin	Chemical	MESH:D011794
38540171	1714	1724	terpenoids	Chemical	MESH:D013729
38540171	1730	1744	phenolic acids	Chemical	MESH:C017616
38540171	Negative_Correlation	MESH:D007501	MESH:D019190
38540171	Association	MESH:D007501	MESH:D010743
38540171	Association	MESH:D009202	2879
38540171	Association	MESH:D050197	4780

